A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Inclusion criteria

• Capable of giving signed informed consent
• Participant must be 18 or age of legal maturity to 55 years of age inclusive, at the time of signing the informed consent
• Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, laboratory tests, physical, cardiac, and neurologic examination
• Body mass index (BMI) within the range [18 - 30] kg/m^2 (inclusive), with bodyweight above/equal to 50 kg
• Male
• Study participants of reproductive potential must agree to use adequate contraception when sexually active during the study period and for at least 3 months after the last dose of study intervention, and refrain from donating sperm during this period
• Participant must have venous access sufficient to allow blood sampling as required by the protocol
• Participant must be willing to undergo multiple blood draws as required by the protocol
• Participant must be willing to comply with dietary and fluid requirements during the treatment period (including abstaining from alcohol use)
• Ability to understand and follow study-related instructions

Exclusion criteria

• Existing relevant diseases of vital organs (e.g., liver diseases, heart diseases, gastrointestinal diseases, interstitial lung disease), central nervous system (for example seizures) or other organs (e.g., diabetes mellitus)
• Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study intervention will not be normal
• Any relevant diseases within 4 weeks prior to the first study intervention administration as judged by the investigator
• A medical history of risk factors for Torsades de pointes (e.g., family history of long QT syndrome) or other clinically significant arrhythmias as judged by the investigator
• Known history of hypersensitivity (or known allergic reaction) to BAY2927088-related compounds, or any components of the formulation
• History of known or suspected malignant tumors
• Participants with any type of psychiatric disorder, especially any mood disorders including medical history with suicidal ideation and/or suicide attempts, which may disable the participant to consent
• Any condition which may result in longer than usual retention of urine or feces in the body, such as pronounced (less than one defecation in 3 days) constipation or symptomatic prostatic hypertrophy
• Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column]), during work or during participation in a clinical study in the period of 1 year prior to screening
• Participant will be excluded when he participated in another study with a radiation burden of 0.1 - 1 mSv (inclusive) in the period of 1 year prior to screening; 1.1 - 2 mSv (inclusive) in the period of 2 years prior to screening; 2.1 - 3 mSv (inclusive) in the period of 3 years prior to screening, etc. (add 1 year per 1 mSv)